Anixa Biosciences announces European patent on ovarian cancer vaccine technology

Anixa Biosciences announced that its partner, Cleveland Clinic, has received an “Intention to Grant” notice from the European Patent Office for the patent application titled “Ovarian Cancer Vaccines.” Dr. Amit Kumar, Chairman and CEO of Anixa, stated, “Having recently been granted a U.S. patent for this novel ovarian cancer vaccine technology, we are delighted to receive the EPO’s intention-to-grant notice, as a European patent would extend protection of the technology to additional potential markets.”